05.06.19
Swissfillon AG, a fill and finish contract manufacturing organization (CMO) for complex pharmaceutical and biopharmaceutical products, has successfully completed a facility inspection of its GMP manufacturing site, located in Visp, Switzerland.
The Swissfillon production site in Visp was assessed by the U.S. FDA between April 15 and 24, 2019. The focus was on the fill and finish process related to a highly delicate drug product and produced an overall positive evaluation from the auditors.
Swissfillon has been serving the European market with its integrated capabilities to manage highly viscous, oil-based drugs that are complex to fill, besides bubble-free filling solutions for cartridge and syringe-based drug delivery systems.
Due to this achievement, Swissfillon says it is now well-positioned to address the growing needs of the U.S. biopharmaceutical industry.
“We are extremely proud of such an outstanding result, which stems from the long-term commitment and experience of all our technicians and scientists,” said Daniel Kehl, chief executive officer, Swissfillon. “We have designed our facility with a reduced footprint for efficient and flexible small-scale manufacturing, which is ideal for the current needs of biopharma customers. This milestone marks a further step in our company’s development plan to provide solutions for a high-standard pharmaceutical environment, complying with the most stringent quality requirements.”
The Swissfillon production site in Visp was assessed by the U.S. FDA between April 15 and 24, 2019. The focus was on the fill and finish process related to a highly delicate drug product and produced an overall positive evaluation from the auditors.
Swissfillon has been serving the European market with its integrated capabilities to manage highly viscous, oil-based drugs that are complex to fill, besides bubble-free filling solutions for cartridge and syringe-based drug delivery systems.
Due to this achievement, Swissfillon says it is now well-positioned to address the growing needs of the U.S. biopharmaceutical industry.
“We are extremely proud of such an outstanding result, which stems from the long-term commitment and experience of all our technicians and scientists,” said Daniel Kehl, chief executive officer, Swissfillon. “We have designed our facility with a reduced footprint for efficient and flexible small-scale manufacturing, which is ideal for the current needs of biopharma customers. This milestone marks a further step in our company’s development plan to provide solutions for a high-standard pharmaceutical environment, complying with the most stringent quality requirements.”
